- Home
- YQ vs PRTG Comparison
YQ vs PRTG Comparison
Compare YQ & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- PRTG
- Stock Information
- Founded
- YQ 2012
- PRTG 1973
- Country
- YQ China
- PRTG British Virgin Islands
- Employees
- YQ N/A
- PRTG N/A
- Industry
- YQ Other Consumer Services
- PRTG Oil & Gas Production
- Sector
- YQ Real Estate
- PRTG Energy
- Exchange
- YQ Nasdaq
- PRTG Nasdaq
- Market Cap
- YQ 11.7M
- PRTG 11.1M
- IPO Year
- YQ 2020
- PRTG N/A
- Fundamental
- Price
- YQ $1.79
- PRTG $9.21
- Analyst Decision
- YQ
- PRTG
- Analyst Count
- YQ 0
- PRTG 0
- Target Price
- YQ N/A
- PRTG N/A
- AVG Volume (30 Days)
- YQ 51.2K
- PRTG 3.7M
- Earning Date
- YQ 06-04-2025
- PRTG 04-29-2025
- Dividend Yield
- YQ N/A
- PRTG N/A
- EPS Growth
- YQ N/A
- PRTG N/A
- EPS
- YQ N/A
- PRTG N/A
- Revenue
- YQ $25,922,648.00
- PRTG N/A
- Revenue This Year
- YQ N/A
- PRTG N/A
- Revenue Next Year
- YQ N/A
- PRTG N/A
- P/E Ratio
- YQ N/A
- PRTG N/A
- Revenue Growth
- YQ 10.68
- PRTG N/A
- 52 Week Low
- YQ $1.26
- PRTG $2.10
- 52 Week High
- YQ $3.19
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- YQ 52.34
- PRTG 61.62
- Support Level
- YQ $1.51
- PRTG $6.75
- Resistance Level
- YQ $1.98
- PRTG $15.82
- Average True Range (ATR)
- YQ 0.26
- PRTG 2.21
- MACD
- YQ 0.03
- PRTG 0.23
- Stochastic Oscillator
- YQ 51.35
- PRTG 41.78
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers to assist students, teachers, schoolmasters, and educational authorities across China to achieve data-driven teaching, learning, and assessment. Geographically group operates in China.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.